5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.81▼ | 2.84▼ | 2.83▼ | 2.90▼ | 3.01▼ |
MA10 | 2.82▼ | 2.84▼ | 2.83▼ | 2.95▼ | 3.29▼ |
MA20 | 2.83▼ | 2.84▼ | 2.87▼ | 3.03▼ | 3.32▼ |
MA50 | 2.84▼ | 2.89▼ | 2.93▼ | 3.39▼ | 2.49▲ |
MA100 | 2.84▼ | 2.95▼ | 3.00▼ | 3.26▼ | 1.90▲ |
MA200 | 2.88▼ | 3.01▼ | 3.10▼ | 2.63▲ | 1.44▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.003▼ | 0.002▲ | 0.000▼ | -0.007▼ | -0.140▼ |
RSI | 41.275▼ | 36.799▼ | 35.257▼ | 34.995▼ | 45.888▼ |
STOCH | 16.038▼ | 38.451 | 35.100 | 10.965▼ | 13.374▼ |
WILL %R | -88.889▼ | -93.333▼ | -96.552▼ | -100.000▼ | -100.000▼ |
CCI | -108.224▼ | -172.902▼ | -122.721▼ | -152.266▼ | -123.386▼ |
Saturday, September 06, 2025 08:23 AM
Key Insights Significant control over Akebia Therapeutics by individual investors implies that the general public ...
|
Thursday, August 28, 2025 05:00 AM
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
|
Thursday, August 21, 2025 06:00 AM
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
17/09/25 | 2.83 | 2.88 | 2.80 | 2.80 | 2,567,846 |
16/09/25 | 2.91 | 2.945 | 2.81 | 2.83 | 3,063,676 |
15/09/25 | 2.97 | 3.02 | 2.92 | 2.92 | 2,490,149 |
12/09/25 | 2.99 | 2.99 | 2.91 | 2.95 | 2,253,961 |
11/09/25 | 2.935 | 2.99 | 2.93 | 2.99 | 2,409,953 |
10/09/25 | 3.015 | 3.05 | 2.92 | 2.93 | 2,823,403 |
09/09/25 | 3.13 | 3.1353 | 2.96 | 3.00 | 3,358,646 |
08/09/25 | 2.97 | 3.15 | 2.92 | 3.13 | 5,676,598 |
05/09/25 | 3.02 | 3.0499 | 2.90 | 2.96 | 5,955,866 |
04/09/25 | 3.11 | 3.14 | 3.01 | 3.02 | 4,058,237 |
|
|
||||
|
|
||||
|
|